PhRMA expresses 'serious concerns' with Trump drug pricing proposals

The Hill: The main drug industry lobbying group on Tuesday said that it had "serious concerns" with major elements of President Trump's new plan to bring down drug prices.

In the first extended remarks on the plan since Trump unveiled it last Friday, Lori Reilly, an executive vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA), pointed to several proposals she said would harm patient access to drugs.

Democrats and some other observers have criticized Trump's plan for not going far enough to take on drug companies. For example, the plan does not include a call for Medicare to negotiate drug prices directly.

Read article